Journal of inflammation research · 2025
Role of ILC2s as Potential Effector Cells of IL25-Mediated Type 2 Inflammation in Chronic Rhinosinusitis with Nasal Polyps in China.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Qiuning, Song Ruibiao, Ba Yunpeng, Geng Junjie, Liu Xuyang, Liang Tingting, Wang Shaochi, Zhao Yulin
Аннотация
INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by Th2-type inflammation and is associated with dysregulated interleukin-25 (IL-25) expression. Type II innate lymphoid cells (ILC2s), as potential effector cells of IL-25, may contribute to the pathogenesis of CRSwNP. However, their specific role in nasal polyp (NP) tissues, particularly in Chinese patients, remains insufficiently understood.
METHODS: Nasal polyp (NP) tissue and turbinate mucosa (TM) were collected from 37 Chinese CRSwNP patients undergoing surgery. TM samples from 7 patients with pituitary tumors were used as controls. IL-25 expression, Th2 cytokines, phosphorylated STAT3 (p-STAT3), and ILC2 levels were assessed via immunohistochemistry, flow cytometry, and ELISA. Isolated ILC2s from NP tissues were stimulated with IL-25, with or without limonin treatment, to evaluate downstream cytokine production and STAT3 activation.
RESULTS: Compared to control TM, both NPs and TM from CRSwNP patients showed elevated IL-25 expression. NP tissues exhibited increased p-STAT3 levels and overexpression of Th2 cytokines. ILC2s were significantly more abundant in NPs and TM of CRSwNP patients. Upon IL-25 stimulation, NP-derived ILC2s produced higher levels of IL-5 and IL-13, accompanied by enhanced STAT3 phosphorylation. Limonin treatment significantly reduced both STAT3 activation and Th2 cytokine production in IL-25-stimulated NP tissues.
CONCLUSION: ILC2s function as key effector cells of IL-25 in CRSwNP, promoting type-2 inflammation via the STAT3 signaling pathway. Limonin attenuates this response and may serve as a promising therapeutic agent for CRSwNP by targeting IL-25/STAT3-driven ILC2 activation.
METHODS: Nasal polyp (NP) tissue and turbinate mucosa (TM) were collected from 37 Chinese CRSwNP patients undergoing surgery. TM samples from 7 patients with pituitary tumors were used as controls. IL-25 expression, Th2 cytokines, phosphorylated STAT3 (p-STAT3), and ILC2 levels were assessed via immunohistochemistry, flow cytometry, and ELISA. Isolated ILC2s from NP tissues were stimulated with IL-25, with or without limonin treatment, to evaluate downstream cytokine production and STAT3 activation.
RESULTS: Compared to control TM, both NPs and TM from CRSwNP patients showed elevated IL-25 expression. NP tissues exhibited increased p-STAT3 levels and overexpression of Th2 cytokines. ILC2s were significantly more abundant in NPs and TM of CRSwNP patients. Upon IL-25 stimulation, NP-derived ILC2s produced higher levels of IL-5 and IL-13, accompanied by enhanced STAT3 phosphorylation. Limonin treatment significantly reduced both STAT3 activation and Th2 cytokine production in IL-25-stimulated NP tissues.
CONCLUSION: ILC2s function as key effector cells of IL-25 in CRSwNP, promoting type-2 inflammation via the STAT3 signaling pathway. Limonin attenuates this response and may serve as a promising therapeutic agent for CRSwNP by targeting IL-25/STAT3-driven ILC2 activation.